Investor New Enterprise Associates 16, L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by New Enterprise Associates 16, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-08-18 13D/A MRKR / Marker Therapeutics, Inc. 1,625,678 1,625,678
2025-08-11 13D/A TRVI / Trevi Therapeutics, Inc. 15,074,080 15,074,080
2025-05-16 13D/A ALLK / Allakos Inc. 6,147,260 0
2025-03-20 13D/A TRVI / Trevi Therapeutics, Inc. 15,074,080 15,074,080
2024-12-23 13D/A MRKR / Marker Therapeutics, Inc. 1,071,428 1,625,678
2024-11-08 13D/A TRVI / Trevi Therapeutics, Inc. 15,074,080 15,074,080
2024-05-21 13D/A TRVI / Trevi Therapeutics, Inc. 14,370,376 15,074,080
2024-05-17 13D/A MRKR / Marker Therapeutics, Inc. 14,464,285 1,071,428
2024-05-13 13D/A BDTX / Black Diamond Therapeutics, Inc. 3,448,757 4,546,947
2023-12-29 13D/A MIRM / Mirum Pharmaceuticals, Inc. 2,186,243
2023-06-23 13D/A MIRM / Mirum Pharmaceuticals, Inc. 4,186,243 2,186,243
2022-10-28 13D/A AKUS / Akouos Inc 4,294,207 4,294,207
2022-10-11 13D ALLK / Allakos Inc. 6,147,260
2022-05-27 13D/A GNCA / Genocea Biosciences Inc 15,414,495
2022-04-25 13D/A TRVI / Trevi Therapeutics, Inc. 7,789,850 14,370,376
2022-01-05 13D/A MTCR / Metacrine Inc 3,060,527
2021-11-02 13D/A TRVI / Trevi Therapeutics, Inc. 5,937,998 7,789,850
2021-04-14 13D/A GNCA / Genocea Biosciences Inc 15,414,495 15,414,495
2021-04-14 13D/A GNCA / Genocea Biosciences Inc 16,972,828 15,414,495
2021-03-26 13D/A MRKR / Marker Therapeutics, Inc. 8,750,000 14,464,285
2021-03-11 13D/A ALLK / Allakos Inc. 2,266,675
2020-09-28 13D MTCR / Metacrine Inc 3,060,527
2020-08-03 13D/A GNCA / Genocea Biosciences Inc 8,968,617 16,972,828
2020-07-07 13D AKUS / Akouos Inc 4,294,207
2020-04-16 13D/A TRVI / Trevi Therapeutics, Inc. 4,438,562 5,937,998
2020-02-13 13D BDTX / Black Diamond Therapeutics, Inc. 3,448,757
2019-07-30 13D MIRM / Mirum Pharmaceuticals, Inc. 4,186,243
2019-06-28 13D/A GNCA / Genocea Biosciences Inc 49,943,669 8,968,617
2019-05-28 13D/A XFOR / X4 Pharmaceuticals, Inc.
2019-05-20 13D TRVI / Trevi Therapeutics, Inc. 4,438,562
2019-02-22 13D/A GNCA / Genocea Biosciences Inc 37,500,000 49,943,669
2018-10-25 13D MRKR / Marker Therapeutics, Inc. 8,750,000
2018-07-27 13D ALLK / Allakos Inc. 2,266,675
2018-01-26 13D GNCA / Genocea Biosciences Inc 37,500,000
2017-11-29 13D XFOR / X4 Pharmaceuticals, Inc. 2,000,000